Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion
Investor's Business Daily • • business
Key Points:
- Novo Nordisk has made a $10 billion offer to acquire obesity-focused biotech Metsera, surpassing Pfizer's $8.1 billion bid in an escalating takeover battle.
- Metsera's stock surged 20.5% following Novo's bid, while Pfizer and Novo Nordisk shares declined modestly amid the competitive acquisition efforts.
- Pfizer initially pledged up to $4.9 billion for Metsera but was outbid first by Novo's $6.5 billion unsolicited offer and now by the revised $10 billion proposal.
- The acquisition is strategically important as Pfizer struggles to establish a weight-loss franchise, while Novo Nordisk, a market leader, faces growing competition from Eli Lilly’s rapidly expanding weight-loss drug sales.
